DOCSLIB.ORG

A-3 Table of Surgical Procedures (TOSP)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A-3 Table of Surgical Procedures (TOSP) Annex A-3 Ministry of Health TABLE OF SURGICAL PROCEDURES (Updated as of 12 January 2016) A-3-1 CONFIDENTIAL Annex A-3 TABLE OF CONTENTS SA - Integumentary ........................................................................... 3 SB - Musculoskeletal ....................................................................... 11 SC - Respiratory .............................................................................. 32 SD - Cardiovascular ........................................................................ 35 SE - Hemic & Lymphatic ................................................................. 42 SF - Digestive .................................................................................. 44 SG - Urinary .................................................................................... 58 SH - Male Genital ............................................................................ 63 SI - Female Genital ......................................................................... 66 SJ - Endocrine ................................................................................. 74 SK - Nervous ................................................................................... 75 SL - Eye ........................................................................................... 83 SM - ENT ......................................................................................... 90 The Table of Surgical Procedures (TOSP) is an exhaustive list of procedures with table ranking 1A to 7C, for which Medisdave / MediShield Life can be claimed. Any procedures not listed or without a table ranking 1A to 7C are not claimable. Specifically, Minor Surgical Procedures (procedures with table ranking “MSP”) are procedures which the TOSP review committee decided to be non- claimable. The list of MSPs is non-exhaustive, i.e. procedures not in the TOSP and not a MSP are still not claimable. A-3-2 CONFIDENTIAL SA - INTEGUMENTARY S/N New Description Table Classification Current Code code 1 SA700B Botulinum toxin therapy for movement disorders MSP Existing SA700B 2 SA800B Breast (nipple), Various lesions, Graft and/or flap 4B Uptabled / SA800B reconstruction (bilateral) Description Change 3 SA801B Breast (nipple), Various lesions, Graft and/or flap 4A Uptabled / SA801B reconstruction (unilateral) Description Change 4 SA803B Breast, Diffuse hypertrophy, Reduction >250g 4B Existing SA803B (unilateral) 5 SA802B Breast, Diffuse Hypertrophy, Reduction 6A Uptabled SA802B Mammoplasty >500g (bilateral) 6 SA805B Breast, drooping, mastopexy/reduction 4A Existing SA805B (unilateral) 7 SA804B Breast, Drooping, mastopexy/reduction (bilateral) 5B Uptabled SA804B 8 SA701B Breast, Ductal Lesions, Microdochectomy 3A Existing SA701B (bilateral) 9 SA702B Breast, Ductal Lesions, Microdochectomy 2C Existing SA702B (unilateral) 10 SA806B Breast, Gynecomastia, Reduction (bilateral) 4A Existing SA806B 11 SA807B Breast, Gynecomastia, Reduction (unilateral) 3A Existing SA807B 12 SA808B Breast, Hypoplasia, Augmentation Mammoplasty 4A Existing SA808B (prosthetic and bilateral) 13 SA809B Breast, Hypoplasia, Augmentation Mammoplasty 3A Existing SA809B (prosthetic and unilateral) 14 SA811B Breast, Inverted Nipple, Surgical Eversion 2C Existing SA811B (unilateral) 15 SA810B Breast, Inverted Nipples, Surgical Eversion 3A Existing SA810B (bilateral) 16 SA812B Breast, Lump (single), Excision biopsy 2C Existing SA812B 17 SA705B Breast, Lump, more than 4 cm (removal) with 4A Existing SA705B parenchymal flap closure (unilateral/bilateral) 18 SA703B Breast, Lump, Percutaneous Biopsy under MRI 2C Existing SA703B 19 SA813B Breast, Lumps (multiple/bilateral), Excision 3A Existing SA813B biopsy 20 SA706B Breast, Lumps, Imaging Guided Vacuum 2C Existing SA706B assisted Biopsy / Mammotome, > 1 lesions 21 SA704B Breast, Lumps, Imaging Guided Vacuum 2B Existing SA704B assisted Biopsy / Mammotome, Single lesion 22 SA814B Breast, Post mastectomy, implant/expander 5A Existing SA814B reconstruction (bilateral) 23 SA815B Breast, Post mastectomy, implant/expander 4A Existing SA815B reconstruction (unilateral) 24 SA816B Breast, Post Mastectomy, latissmus dorsi 6C Existing SA816B pedicled flap with or without implant reconstruction (bilateral) 25 SA817B Breast, Post Mastectomy, latissmus dorsi 5C Existing SA817B pedicled flap with or without implant reconstruction (unilateral) 26 SA818B Breast, Post Mastectomy, Reconstruction using 7A Existing SA818B pedicled Transverse Rectus Abdominis Musculocutaneous Flap (bilateral) A-3-3 CONFIDENTIAL SA - INTEGUMENTARY S/N New Description Table Classification Current Code code 27 SA713B Breast, Post mastectomy, reconstruction using 6A Existing SA713B pedicled transverse rectus abdominis musculocutaneous flap (unilateral) 28 SA819B Breast, Post mastectomy, reconstruction using 7C Existing SA819B transverse rectus abdominis free musculocutaneous flap (unilateral) 29 SA820B Breast, Post Prosthetic Contraction, 3A Existing SA820B Capsulotomy (bilateral) 30 SA821B Breast, Post Prosthetic Contraction, 2C Existing SA821B Capsulotomy (unilateral) 31 SA825B Breast, Tumor (malignant), Radical mastectomy 5C Existing SA825B with/without Axiliary Clearance 32 SA826B Breast, Tumor (malignant), Simple Mastectomy 4A Existing SA826B 33 SA824B Breast, Tumor (malignant), Simple Mastectomy 5A Existing SA824B with Axiliary Clearance, with/without Sentinel Node Biopsy 34 SA827B Breast, Tumor (malignant), Simple Mastectomy 4C Existing SA827B with Sentinel Node Biopsy/ Axiliary Node Sampling 35 SA822B Breast, Tumor (malignant), Wide Excision/ 3B Existing SA822B Lumpectomy/Segmental Mastectomy/ Partial Mastectomy 36 SA823B Breast, Tumor (malignant), Wide Excision/ 4B Existing SA823B Lumpectomy/Segmental Mastectomy/ Partial Mastectomy, with Axiliary Clearance, with/without Sentinel Node Biopsy 37 SA707B Breast, Tumor (malignant), Wide Excision/ 3C Existing SA707B Lumpectomy/Segmental Mastectomy/ Partial Mastectomy, with Sentinel Node Biopsy/ Axiliary Node Sampling 38 SA708B Breast, Various Lesions, Percutaneous MSP Existing SA708B Aspiration under Ultrasound 39 SA828B Breast, Various lesions, Subcutaneous 4A Existing SA828B mastectomy bilateral, excluding gynaecomastia 40 SA830B Breast, Various lesions, subcutaneous 3C Existing SA830B mastectomy unilateral, excluding gynaecomastia 41 SA829B Breast, Various Lesions, Trucut Biopsy 1A Existing SA829B 42 SA709B Breast, Various Lesions, Trucut Biopsy, 1C Existing SA709B ultrasound guided or stereotactic (multiple) 43 SA710B Breast, Various Lesions, Trucut Biopsy, 1B Existing SA710B ultrasound guided or stereotactic (single) 44 SA711B Breast, Various Lesions, wire localisation, 3B Existing SA711B excision (multiple) 45 SA712B Breast, Various Lesions, wire localisation, 3A Existing SA712B excision (single) 46 SA800F Fascia (deep), Rupture with Herniated Muscle, 1B Existing SA800F Repair 47 SA800H Hand, Burns (major), Excision and Split Skin 4A Existing SA800H Graft 48 SA800M Mucous membrane (ear/nose/eyelid) 3A Existing SA800M avulsion/complex laceration, full thickness repair 49 SA801M Mucous Membrane, Deep Laceration/Multiple 3A Existing SA801M Lacerations, Repair A-3-4 CONFIDENTIAL SA - INTEGUMENTARY S/N New Description Table Classification Current Code code 50 SA802M Mucous Membrane, Superficial Laceration 1B Existing SA802M equal/less than 7cm, Repair 51 SA803M Mucous Membrane, Superficial Laceration(s) 2B Existing SA803M more than 7 cm, Repair 52 SA804M Mucous Membrane, Tumor/Cyst/Ulcer/Scar, 2B Existing SA804M Excision 53 SA805M Muscle and Deep Tissue, Foreign Body, 2C Existing SA805M Removal 54 SA700R Radiotherapy, Endoluminal Brachytherapy: 2B Existing SA700R Oesophagus, Nasopharyngeal carcinoma (NPC), Hepatobiliary, Cardiac, Lung, Others 55 SA701R Radiotherapy, Interstitial brachytherapy 4B Existing SA701R (with/without open surgery) 56 SA702R Radiotherapy, Interstitial brachytherapy (without 5A Existing SA702R open surgery): Prostate 57 SA703R Radiotherapy, Intracavitary Brachytherapy 2C Existing SA703R (Multi-channel): Cervix, Others 58 SA704R Radiotherapy, Intracavitary Brachytherapy 2A Existing SA704R (Single channel): Endometrium, others 59 SA705R Radiotherapy, Intra-operative Radiotherapy 3A Existing SA705R (electrons or kilovoltage): Breast, Sarcoma, Upper GI, Lower GI, Other sites 60 SA849S Skin & Subcutaneous, Pre-septal/PeriOrbital 2A Existing SA849S Dermoid/Lesion, Excision 61 SA804S Skin & subcutaneous, Scar revision - face & 1C Existing SA804S neck (< 3cm) 62 SA700S Skin (Upper Limb), Open Wound, Major 2A Existing SA700S Desloughing 63 SA803S Skin and Subcutaneous 3B Existing SA803S tissue(ear/nose/eyelid/face) complex lacerations, repair 64 SA842S Skin and Subcutaneous tissue, Lacerations 3B Existing SA842S (deep >3cm/multiple) lacerations, repair/toilet & suture, with/without debridement 65 SA800S Skin and Mucous Membrane, Various Lesions, 1B Existing SA800S Excision Biopsy 66 SA805S Skin and Subcutaneous Tissue (face and neck), 2B Existing SA805S Scar of more than 3cm, Revision 67 SA806S Skin and Subcutaneous Tissue, Burns, 2A Existing SA806S Escharotomy (extensive) 68 SA807S Skin and Subcutaneous Tissue, Burns, 1A Existing SA807S Escharotomy (limited) 69 SA808S Skin and Subcutaneous Tissue, Burns, Excision 5A Existing SA808S and Major Flap Repair 70 SA809S Skin and Subcutaneous Tissue, Burns, Excision 4A Existing SA809S and Major Full Thickness Graft 71 SA810S Skin and Subcutaneous Tissue, Burns, Excision 3A Existing SA810S and Small Full Thickness Graft 72 SA811S Skin and Subcutaneous Tissue,
Load more

Recommended publications
  • Breast Reduction with Dermoglandular Flaps Tessier’S “Total Dermo-Mastopexy” and the “Yin-Yang Technique”
    BREAST SURGERY Breast Reduction With Dermoglandular Flaps Tessier’s “Total Dermo-Mastopexy” and the “Yin-Yang Technique” Francesco Gargano, MD, PhD,* Paul Tessier, MD,† and S. Anthony Wolfe, MD‡ skin and the gland and less “isolation” of the areola from the skin Abstract: The use of dermoglandular flaps in reduction mastopexy was and its vascular and nerve network. Because of this, there was advocated by Paul Tessier, who never published his method, but had actually greater security for the nipple and the skin flaps; but, the most rapid almost finished the following article before his death in June 2008. Dr. method seemed also to be a reason for its choice. Tessier is acknowledged as the “father” of craniofacial surgery, but he had The Ragnell procedure, and particularly the Biesenberger interest in aesthetic surgery, and was quite proud of the technique he procedure, has been criticized because of a lack of vascular security had developed using dermoglandular flaps in reduction mammoplasty. He associated with an extended dissection between the skin and the had literally hundreds of techniques and methods that he had developed but gland. During 1947 or 1948, I observed Mcindoe brilliantly per- which never found their way into print, both because of his enormous forming a Biesenberger procedure, and noted a good shape of the surgical schedule, and perhaps his self-imposed standards for anything that breast at the end of the operation. Thus, I began using the Biesen- he published, which were almost impossibly high. The technique proposed berger procedure in this pure form, but was never satisfied with my by Dr.
    [Show full text]
  • Burns, Surgical Treatment
    Philippine College of Surgeons Dear PCS Fellows, We at the PCS Committee on HMO, RVS, & PHIC & The PCS Board of Regents are pleased to announce the Adoption of PAHMOC of our new & revised RVS. We are currently under negotiations with them with regard to the multiplier to be used to arrive at our final professional Fees. Rest assured that we will have a graduated & staggered increase of PF thru the years from what we are currently receiving due to the proposed yearly increments in the multiplier. To those Fellows who haven’t signed the USA (Universal Service Agreement found here in our PCS website) please be reminded to sign and submit to the PCS Secretariat, as only those who did and are in good standing (updated annual dues) will be eligible to avail of the benefits of the new RVS scale. Indeed, we are hoping & looking forward to a merrier 2020 Christmas for our Fellows. Yours truly, FERNANDO L. LOPEZ, MD, FPCS Chairman Noted by: JOSELITO M. MENDOZA, MD, FPCS Regent-in-Charge JOSE ANTONIO M. SALUD, MD, FPCS President For many years now the PCS Committee on HMO & RUV has been compiling, with the assistance of the different surgical subspecialties, a new updated list of RUV for each procedure to replace the existing manual of 2009. This new version not only has a more complete listing of cases but also includes the newly developed procedures particularly for all types of minimally invasive operations. Sometime last year, the Department of Health released Circular 2019-0558 on the Public Access to the Price Information by all Health Providers as required by Section 28.16 of the IRR of the Universal Health Care Act.
    [Show full text]
  • Breast Lift (Mastopexy)
    BREAST LIFT (MASTOPEXY) The operation for breast lift is aimed at elevation of your normal breast tissue. This operation will not affect back, neck and shoulder pain due to the other problems such as arthritis. It also is not a weight loss procedure for obesity, nor will this operation correct stretch marks which may already be present. Often times this opera- tion is done to recreate symmetry if there is a large discrepancy in the shape of the two breasts. This operation has inherent risks asso- ciated with any surgery including infection, bleeding and the risk associated with the general anesthesia which is necessary. In addi- tion this operation results in scars around the areola and beneath the breast as has been described. It is impossible to lift the breasts with- out obvious scars. Although attempts and techniques will be made to minimize the scarring, this is an area of the body in which scars tend to widen due to location and the weight of the breasts. Revi- sion of these scars may be possible depending on their appearance following a 9-12 month healing period. In addition, these widened scars may be the result of delayed healing resulting from a small area of skin death in the portion where the two incisions come to- gether. This area is prone to a partial separation of the scar due to the tension and often times marginal blood supply in this area. This usually can be treated with local wound care including hydro- gen peroxide washes and application of a antibiotic ointment.
    [Show full text]
  • Breast Uplift (Mastopexy) Procedure Aim and Information
    Breast Uplift (Mastopexy) Procedure Aim and Information Mastopexy (Breast Uplift) The breast is made up of fat and glandular tissue covered with skin. Breasts may change with variable influences from hormones, weight change, pregnancy, and gravitational effects on the breast tissue. Firm breasts often have more glandular tissue and a tighter skin envelope. Breasts become softer with age because the glandular tissue gradually makes way for fatty tissue and the skin also becomes less firm. Age, gravity, weight loss and pregnancy may also influence the shape of the breasts causing ptosis (sagging). Sagging often involves loss of tissue in the upper part of the breasts, loss of the round shape of the breast to a more tubular shape and a downward migration of the nipple and areola (dark area around the nipple). A mastopexy (breast uplift) may be performed to correct sagging changes in the breast by any one or all of the following methods: 1. Elevating the nipple and areola 2. Increasing projection of the breast 3. Creating a more pleasing shape to the breast Mastopexy is an elective surgical operation and it typifies the trade-offs involved in plastic surgery. The breast is nearly always improved in shape, but at the cost of scars on the breast itself. A number of different types of breast uplift operations are available to correct various degrees of sagginess. Small degrees of sagginess can be corrected with a breast enlargement (augmentation) only if an increase in breast size is desirable, or with a scar just around the nipple with or without augmentation.
    [Show full text]
  • Rwanda Medical Procedure Code Database
    Rwanda Medical Procedure Code Database RMP Code Detailed Nomenclature Mapped to local nomenclature Specialty Administrative Sub-classification: A2001 Medical certificate Medical certificate A2002 Medical report Medical report A2003 Medical expertise Medical expertise A2004 Postmortem report Postmortem report A2005 Second opinion Second opinion A2006 Birth certificate Birth certificate A2007 Death certificate Death certificate A2008 Birth certificate [copy] Birth certificate [copy] A2009 Death certificate [copy] Death certificate [copy] A2010 Medical file Medical file A2011 Medical card Medical card A2012 Prescription Prescription A2013 Certificate of physical aptitude Certificate of physical aptitude A2014 Ambulance service per kilometer Ambulance service per kilometer 1 of 285 Rwanda Medical Procedure Code Database RMP Code Detailed Nomenclature Mapped to local nomenclature Specialty Allied professional services Sub-classification: Autism/PDD 82000 psychology health service provided to a child, aged under 13 years, by an eligible psychologist where:[a] the child is Autism/PDD assistance with diagnosis / referred by an eligible practitioner for the purpose of assisting the practitioner with their diagnosis of the child; or[b] the contribution to a treatment plan by psychologist child is referred by an eligible practitioner for the purpose of contributing to the child`s pervasive developmental disorder [pdd] or disability treatment plan, developed by the practitioner; and[c] for a child with pdd, the eligible practitioner is a consultant
    [Show full text]
  • Breast Cancer Screening and Chemoprevention
    Management of Breast Diseases Ismail Jatoi Manfred Kaufmann (Eds.) Management of Breast Diseases Dr. Ismail Jatoi Prof. Dr. Manfred Kaufmann Head, Breast Care Center Breast Unit National Naval Medical Center Director, Women’s Hospital Uniformed Services University University of Frankfurt of the Health Sciences Theodor-Stern-Kai 7 4301 Jones Bridge Rd. 60590 Frankfurt Bethesda, MD 20814 Germany USA [email protected] [email protected] ISBN: 978-3-540-69742-8 e-ISBN: 978-3-540-69743-5 DOI: 10.1007/978-3-540-69743-5 Springer Heidelberg Dordrecht London New York Library of Congress Control Number: 2009934509 © Springer-Verlag Berlin Heidelberg 2010 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publishers cannot guarantee the accuracy of any information about dosage and appli- cation contained in this book.
    [Show full text]
  • Systematic Review of Outcomes and Complications in Nonimplant-Based Mastopexy Surgery
    Journal of Plastic, Reconstructive & Aesthetic Surgery (2019) 72, 243–272 Review Systematic review of outcomes and complications in nonimplant-based mastopexy surgery a, d , ∗ b a Pietro G. di Summa , Carlo M. Oranges , William Watfa , c b d Gianluca Sapino , Nicola Keller , Sherylin K. Tay , d b a Ben K. Chew , Dirk J. Schaefer , Wassim Raffoul a Department of Plastic, Reconstructive and Aesthetic Surgery, Lausanne University Hospital, Lausanne, Switzerland b Department of Plastic, Reconstructive, Aesthetic, and Hand Surgery, Basel University Hospital, Basel, Switzerland c Department of Plastic and Reconstructive Surgery, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy d Canniesburn Plastic Surgery Unit, Glasgow Royal Infirmary, Glasgow, Scotland, UK Received 21 April 2018; accepted 28 October 2018 KEYWORDS Summary Background: Mastopexy is one of the most performed cosmetic surgery procedures Mastopexy; in the U.S. Numerous studies on mastopexy techniques have been published in the past decades, Risks; including case reports, retrospective reviews, and prospective studies. However, to date, no Breast lift; study has investigated the overall complications or satisfaction rates associated with the wide Hammock lift; spectrum of techniques. Glandular Objectives: This review aims to assess the outcomes of the various mastopexy techniques, rearrangement; without the use of implants, thus focusing on associated complications, and to provide a sim- Bottoming out; plified classification system. Ptosis Methods: This systematic review was performed in accordance with the PRISMA guidelines. PubMed database was queried in search of clinical studies describing nonprosthetic mastopexy techniques, which reported the technique, indication, and outcomes. Results: Thirty-four studies, published from 1980 through 2016, were included and repre- sented 1888 treated patients.
    [Show full text]
  • Breast Cancer Surgery and Oncoplastic Techniques Aaron D
    Breast CanCer surgery and OnCOplastiC teChniques Aaron D. Bleznak, MD, MBA, FACS Medical Director Breast Program, Ann B. Barshinger Cancer Institute Penn Medicine Lancaster General Health INTRODUCTION For more than a century after the standardiza- compared total mastectomy to lumpectomy (breast tion of the radical mastectomy procedure by William conserving surgery or BCS) with or without radiation Stewart Halsted at Johns Hopkins in the late 19th therapy, demonstrated that the extent of surgery does century, the mainstay of breast cancer treatment not impact cure rates1,2 (Fig. 1). Other randomized has been surgical resection. Removal of the primary trials in the United States and internationally, with breast cancer is curative for those women whose as much as 35 years of follow-up, have confirmed that malignancy has not metastasized to distant sites, and the extent of resection does not affect disease-specific in the current era of mammographic screening, that and overall survival rates.3 is the fortunate status of most women when their Over the ensuing decade after the landmark breast cancer is first diagnosed. NSABP B-06 study, these lessons were incorporated Our understanding of the route of breast can- into oncologic practice, and we achieved a relatively cer metastasis has evolved since Halsted’s time. His steady state in rates of breast conservation (Fig. 2, theory of initial spread via lymphatic channels, which next page). From 2007 to 2016, breast-conserving eventually empty into the vascular system, has evolved surgery was used in approximately 60% of women into our current appreciation that primary spread is with breast cancer cared for in hospitals accredited hematogenous.
    [Show full text]
  • Mammary Ductoscopy in the Current Management of Breast Disease
    Surg Endosc (2011) 25:1712–1722 DOI 10.1007/s00464-010-1465-4 REVIEWS Mammary ductoscopy in the current management of breast disease Sarah S. K. Tang • Dominique J. Twelves • Clare M. Isacke • Gerald P. H. Gui Received: 4 May 2010 / Accepted: 5 November 2010 / Published online: 18 December 2010 Ó Springer Science+Business Media, LLC 2010 Abstract terms ‘‘ductoscopy’’, ‘‘duct endoscopy’’, ‘‘mammary’’, Background The majority of benign and malignant ‘‘breast,’’ and ‘‘intraductal’’ were used. lesions of the breast are thought to arise from the epithe- Results/conclusions Duct endoscopes have become lium of the terminal duct-lobular unit (TDLU). Although smaller in diameter with working channels and improved modern mammography, ultrasound, and MRI have optical definition. Currently, the role of MD is best defined improved diagnosis, a final pathological diagnosis cur- in the management of SND facilitating targeted surgical rently relies on percutaneous methods of sampling breast excision, potentially avoiding unnecessary surgery, and lesions. The advantage of mammary ductoscopy (MD) is limiting the extent of surgical resection for benign disease. that it is possible to gain direct access to the ductal system The role of MD in breast-cancer screening and breast via the nipple. Direct visualization of the duct epithelium conservation surgery has yet to be fully defined. Few allows the operator to precisely locate intraductal lesions, prospective randomized trials exist in the literature, and enabling accurate tissue sampling and providing guidance these would be crucial to validate current opinion, not only to the surgeon during excision. The intraductal approach in the benign setting but also in breast oncologic surgery.
    [Show full text]
  • Prevalence of Breast Cancer in Patients Undergoing
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Wits Institutional Repository on DSPACE Prevalence of breast cancer in patients undergoing microdochectomy for a pathological nipple discharge Dr Chiapo Lesetedi AFRCSI(Dublin), FCS(SA) Student Number: 584356 Department of Surgery University of the Witwatersrand E-mail: [email protected] Cell No: 073 394 2043 Supervisors: Dr Sarah Rayne, MRCS, MMed(Wits), FCS(SA), Department of Surgery, University of the Witwatersrand Dr Deirdré Kruger, BSc, PGCHE, PhD(UK), Department of Surgery, University of the Witwatersrand 18th July 2016 Page 1 of 33 TABLE OF CONTENTS DECLARATION……………………………………………………….………………3 ACKNOWLEDGEMENTS……………………………………………………………4 ABSTRACT…………………………………………………………………………….5 CHAPTER 1: INTRODUCTION…………………………………………...…………7 CHAPTER 2: METHODS……………………………………………………..…….10 CHAPTER 3: RESULTS…………………………………………………………….13 CHAPTER 4: DISCUSSION………………………………………………….…….15 CHAPTER 5: REFERENCES………………………………………………………19 APPENDIX 1: APPROVED PROTOCOL………..………………………………..23 APPENDIX 2: DATA RECORDING SHEET…………………..………………….31 APPENDIX 3: ETHICS CLEARANCE……………………………………….……33 Page 2 of 33 DECLARATION I, Chiapo Lesetedi, declare that this research project is my own work. It is being submitted for the degree of Master of Medicine in Surgery at the University of the Witwatersrand, Johannesburg, South Africa. It is submitted by submissible paper format. It has not been submitted before for any degree or examination at this or any other University. ________________ Dr Chiapo Lesetedi 18th July 2016 Page 3 of 33 ACKNOWLEDGEMENTS I would like to thank my supervisors, Dr Sarah Rayne and Dr Deirdré Kruger, who guided me from the start and continuously encouraged and supported me during the writing up of this research project. They have tirelessly assisted in proof reading the project and Dr Kruger also assisted with data analysis and statistics involved.
    [Show full text]
  • Sub-Areolar Duct Excision (SADE) / Affix Patient Label Microdochectomy
    PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Sub-Areolar Duct Excision (SADE) / affix patient label Microdochectomy What is a SADE? SADE is a surgical procedure in which a small portion of the milk ducts from behind the nipple is removed for careful lab analysis to determine the cause of abnormal nipple discharge. Microdochectomy is a procedure to remove a SINGLE discharging duct for the same reason. SADE is the preferred procedure for women who have completed their family and are not anticipating breast feeding in the future. SADE involves the division of all the milk ducts so that breast feeding from that side afterwards is not possible. Microdochectomy is preferred in younger women who wish to be able to breast feed in future. The surgical scar from these two procedures is similar. Why do I need it? In most cases the reasons underlying abnormal nipple discharge are benign (ie non-cancerous), particularly when the breast imaging is normal. However, in a small number of cases with persistent abnormal nipple discharge, the only way to exclude possible underlying early cancerous change is to remove a small portion of the milk ducts for definitive microscopic analysis. Are there any alternatives? py If your clinical examination and breast imaging is normal, then it is commoon practice to wait and watch for a few weeks to see if the discharge settles down on its own. During this pecriod, you are asked to keep diary of discharge. If at the end of this close observation period, thte disc harge continues and there remains enough concern then the only way to exclude serious undnerlying cause for discharge is this surgical procedure.
    [Show full text]
  • Systematic Review and Meta-Analysis of the Diagnostic Accuracy of Ductoscopy in Patients with Pathological Nipple Discharge
    Systematic review Systematic review and meta-analysis of the diagnostic accuracy of ductoscopy in patients with pathological nipple discharge L. Waaijer1,J.M.Simons1,I.H.M.BorelRinkes1,P.J.vanDiest2,H.M.Verkooijen3 and A. J. Witkamp1 Departments of 1Surgery and 2Pathology and 3Imaging Division, University Medical Centre Utrecht, Utrecht, The Netherlands Correspondence to: Ms L. Waaijer, Department of Surgery, University Medical Centre Utrecht, PO Box 85500, G04.228, 3508 GA Utrecht, The Netherlands (e-mail: [email protected]) Background: Invasive surgery remains the standard for diagnosis of pathological nipple discharge (PND). Only a minority of patients with nipple discharge and an unsuspicious finding on conventional breast imaging have cancer. Ductoscopy is a minimally invasive alternative for evaluation of PND. This systematic review and meta-analysis was designed to evaluate the diagnostic accuracy of ductoscopy in patients with PND. Methods: A systematic search of electronic databases for studies addressing ductoscopy in patients with PND was conducted. Two classification systems were assessed. Forany DS , all visualized ductoscopic abnormalities were classified as positive, whereas forsusp DS , only suspicious findings were considered positive. After checking heterogeneity, pooled sensitivity and specificity of DSany and DSsusp were calculated. Results: The search yielded 4642 original citations, of which 20 studies were included in the review. Malignancy rates varied from 0 to 27 per cent. Twelve studies, including 1994 patients, were eligible for meta-analysis. Pooled sensitivity and specificity of DSany were 94 (95 per cent c.i. 88 to 97) per cent and 47 (44 to 49) per cent respectively. Pooled sensitivity and specificity ofsusp DS were 50 (36 to 64) and 83 (81 to 86) per cent respectively.
    [Show full text]